New hope for kids battling tough neuroblastoma
NCT ID NCT07437963
Summary
This study is testing whether adding a new drug called iberdomide to a standard combination of chemotherapy and immunotherapy is safe and more effective for children and young adults with neuroblastoma that has returned, is not responding, or is getting worse after prior treatment. The first part of the study will find the safest dose of iberdomide. The second part will compare the new combination to the standard treatment alone to see if it leads to better outcomes for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.